Theriva Biologics shares are trading higher after the company announced the Data and Safety Monitoring Committee's review outcome for its Phase 1b/2a clinical trial of SYN-004. The DSMC has recommended the study proceed to enroll cohort 3.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics shares rose following a positive review from the Data and Safety Monitoring Committee for its SYN-004 clinical trial, allowing the study to proceed to the next cohort.
October 03, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics' stock price increased after the DSMC recommended the continuation of its SYN-004 clinical trial, indicating positive progress in the study.
The DSMC's recommendation to proceed with the SYN-004 trial is a positive indicator of the trial's progress and safety, which boosts investor confidence and leads to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100